Shares of Amgen (NASDAQ: AMGN) fell by more than 6% on Friday morning after the biotech giant reported clinical details from its FOURIER study. The trial was a long-term cardiovascular outcomes study designed to compare Repatha — Amgen’s PCSK9 inhibitor that is used to lower cholesterol — to a placebo.